Jin Chao-Nan, Chen Jing-Dan, Sheng Ji-Fang
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University.
Department of Infectious Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang Province, China.
Eur J Gastroenterol Hepatol. 2018 Jul;30(7):741-746. doi: 10.1097/MEG.0000000000001134.
In the past few years, a growing body of clinical evidence has highlighted the risk of vitamin D deficiency in patients with chronic hepatitis C and that vitamin D levels are associated with the course of hepatitis C virus (HCV) infection, adverse effects, and treatment response to peginterferon/ribavirin. Recently, studies have found that vitamin D status is related to drug resistance and increased risk of infection in patients with liver cirrhosis. Vitamin D-related gene polymorphisms have been found to explain the interactions between vitamin D deficiency and HCV infection, offering a new perspective toward understanding the current problems such as the development of insulin resistance and racial differences in sustained virological response. Studies have been conducted to determine whether vitamin D supplementation as an adjuvant yields a better result compared with traditional HCV treatment. Here, we provide a brief review of the past and present knowledge of vitamin D in HCV infection.
在过去几年中，越来越多的临床证据凸显了慢性丙型肝炎患者维生素D缺乏的风险，且维生素D水平与丙型肝炎病毒（HCV）感染病程、不良反应以及聚乙二醇干扰素/利巴韦林治疗反应相关。最近，研究发现维生素D状态与肝硬化患者的耐药性及感染风险增加有关。已发现维生素D相关基因多态性可解释维生素D缺乏与HCV感染之间的相互作用，为理解当前问题（如胰岛素抵抗的发展和持续病毒学应答中的种族差异）提供了新视角。已开展研究以确定作为辅助手段补充维生素D与传统HCV治疗相比是否能产生更好的效果。在此，我们简要回顾一下关于维生素D在HCV感染方面的既往和现有认知。
